AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 FEB 4 - (NewsRx.com & NewsRx.net) -- Fixed tumor cells in combination with adjuvant induced protective antitumor immunity in a murine hepatoma model.
According to recent research published in the journal Cancer Letters, "We previously reported that fixed tumor sections induced autologous cytotoxic T lymphocytes (CTL) from human peripheral blood lymphocytes in vitro. Here, we examined whether fixed tumor cells could stimulate in vivo immunity using a murine hepatoma model."
"Vaccination of syngeneic mice with fixed Hepa 1-6 cells in combination with OK-432 and tuberculin as an adjuvant resulted in a significant increase in survival of mice against live Hepa 1-6 cell challenge," said Lan Huang and Tadao Ohno at the Institute of Physical and Chemical Research (RIKEN). "In addition, the splenocytes from vaccinated mice secreted CD4+ T cell-mediated interferon-gamma (IFN-gamma) and exhibited a specific CTL response. These findings suggest that fixed tumor cells combined with an ...
Source: HighBeam Research, Tumor cells plus adjuvant induced immunity against hepatoma.